
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
After the Coast Hearing, IRBs Should Prepare for More Scrutiny by Focusing on Training, Education, and SOPs






